Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762841 | 0.82 | KCNA5 (0.58) | KCNA5KCNH2P2RX7SCN9ASCN5A | |
| SCHEMBL3752465 | 0.82 | KCNA5 (0.69) | ALDH1A1KCNA5KCNH2P2RX7KMT2A | |
| SCHEMBL3750835 | 0.80 | MDM2 (0.57) | ALDH1A1NPSR1KCNA5KCNH2P2RX7 | |
| SCHEMBL3751622 | 0.80 | SCN9A (0.62) | KCNA5KCNH2P2RX7SCN9ASCN5A | |
| SCHEMBL3753733 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KCNA5KCNH2P2RX7KMT2A | |
| SCHEMBL3753672 | 0.79 | MDM2 (0.48) | ALDH1A1NPSR1KCNA5KCNH2P2RX7 | |
| SCHEMBL3762651 | 0.79 | MDM2 (0.46) | KCNA5KCNH2P2RX7SCN9ASCN5A | |
| SCHEMBL3943038 | 0.78 | SCN9A (0.61) | KCNA5KCNH2SCN9ASCN5A | |
| SCHEMBL3750213 | 0.78 | GAA (0.66) | ALDH1A1TSHRNPSR1GAATP53 | |
| SCHEMBL3751140 | 0.77 | MDM2 (0.44) | ALDH1A1NPSR1KCNA5KCNH2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | ALDH1A1 315/4885TSHR 1287/4885NPSR1 806/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | ALDH1A1 310/4885TSHR 1483/4885NPSR1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.